Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine and S-1 for first-line advanced pancreatic cancer
ChiCTR2100054256Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, gemcitabine and tegafur in pancreatic cancer (PC), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
tislelizumabgemcitabinetegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100054256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054256.